Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 12, 2009

Abbott Shells Out $170M for PanGenetics’ Early-Stage Chronic Pain Therapeutic

  • Abbott will pay $170 million up front for global rights to PanGenetics’ Phase I chronic pain treatment, PG110. PanGenetics could also earn up to another $20 million in milestone payments.
    PG110 is a fully humanized nerve growth factor (NGF) antibody currently in development for patients with osteoarthritis. If this Phase I trial is successful, Abbott plans to evaluate the compound in a number of other pain states including chronic lower back pain, cancer pain, and diabetic neuropathic pain.

    NGF is released at sites of tissue damage and inflammation and plays a significant role in the transmission of pain signals by the central nervous system. “The goal for treatment of chronic pain continues to be a potent, long-lasting analgesia that is tolerable for patients without the potential for dependence and abuse,” explians John Leonard, M.D., svp, global R&D, Abbott. “NGF blockers have demonstrated the potential to address all of these needs, making them a promising treatment for chronic pain patients.” 

    This new NGF inhibitor complements Abbott's early-stage pipeline of chronic pain candidates, which span multiple mechanisms including vanilloid cellular receptors, cannabinoid receptors, histamine H3 receptors, and ion-channel targets.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »